The analysts might have been a bit too bullish on Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013), given that the company fell short of expectations when it released its quarterly results last week. Dr. Sulaiman Al Habib Medical Services Group missed earnings this time around, with ر.س3.4b revenue coming in 7.6% below what the analysts had modelled. Statutory earnings per share (EPS) of ر.س1.44 also fell short of expectations by 18%. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Dr. Sulaiman Al Habib Medical Services Group after the latest results.

Following the latest results, Dr. Sulaiman Al Habib Medical Services Group's nine analysts are now forecasting revenues of ر.س15.9b in 2026. This would be a decent 14% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to grow 19% to ر.س8.01. In the lead-up to this report, the analysts had been modelling revenues of ر.س15.8b and earnings per share (EPS) of ر.س7.95 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

It will come as no surprise then, to learn that the consensus price target is largely unchanged at ر.س284. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Dr. Sulaiman Al Habib Medical Services Group analyst has a price target of ر.س320 per share, while the most pessimistic values it at ر.س206. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Dr. Sulaiman Al Habib Medical Services Group shareholders.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We can infer from the latest estimates that forecasts expect a continuation of Dr. Sulaiman Al Habib Medical Services Group'shistorical trends, as the 19% annualised revenue growth to the end of 2026 is roughly in line with the 16% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 11% annually. So although Dr. Sulaiman Al Habib Medical Services Group is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Dr. Sulaiman Al Habib Medical Services Group analysts - going out to 2028, and you can see them free on our platform here.

Even so, be aware that Dr. Sulaiman Al Habib Medical Services Group is showing 1 warning sign in our investment analysis , you should know about...

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.